AU2022311958A1 - Inhibitors of amyloid beta oligomerization and therapeutic uses thereof - Google Patents
Inhibitors of amyloid beta oligomerization and therapeutic uses thereof Download PDFInfo
- Publication number
- AU2022311958A1 AU2022311958A1 AU2022311958A AU2022311958A AU2022311958A1 AU 2022311958 A1 AU2022311958 A1 AU 2022311958A1 AU 2022311958 A AU2022311958 A AU 2022311958A AU 2022311958 A AU2022311958 A AU 2022311958A AU 2022311958 A1 AU2022311958 A1 AU 2022311958A1
- Authority
- AU
- Australia
- Prior art keywords
- amyloid
- subject
- beta
- cells
- oligomerization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203245P | 2021-07-14 | 2021-07-14 | |
| US63/203,245 | 2021-07-14 | ||
| PCT/US2022/073747 WO2023288284A1 (en) | 2021-07-14 | 2022-07-14 | Inhibitors of amyloid beta oligomerization and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022311958A1 true AU2022311958A1 (en) | 2024-02-01 |
Family
ID=84919716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022311958A Pending AU2022311958A1 (en) | 2021-07-14 | 2022-07-14 | Inhibitors of amyloid beta oligomerization and therapeutic uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240325319A1 (https=) |
| EP (1) | EP4370496A4 (https=) |
| JP (1) | JP2024525766A (https=) |
| CN (1) | CN117881650A (https=) |
| AU (1) | AU2022311958A1 (https=) |
| WO (1) | WO2023288284A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025019870A1 (en) * | 2023-07-20 | 2025-01-23 | Northwestern University | Use of neuronal nitric oxide synthase inhibitors in alzheimer's disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US20090143433A1 (en) * | 2004-12-01 | 2009-06-04 | Curt Hendrix | Cocktail for modulation of alzheimer's disease |
| WO2009036275A1 (en) * | 2007-09-13 | 2009-03-19 | Link Medicine Corporation | Treatment of neurodegenerative diseases using indatraline analogs |
| ES2668556T3 (es) * | 2008-11-20 | 2018-05-18 | Northwestern University | Derivados de pirazolona útiles en el tratamiento de esclerosis lateral amiotrófica |
| WO2011059821A2 (en) * | 2009-10-29 | 2011-05-19 | Cambria Pharmaceuticals, Inc. | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis |
-
2022
- 2022-07-14 WO PCT/US2022/073747 patent/WO2023288284A1/en not_active Ceased
- 2022-07-14 US US18/579,307 patent/US20240325319A1/en active Pending
- 2022-07-14 CN CN202280058658.0A patent/CN117881650A/zh active Pending
- 2022-07-14 AU AU2022311958A patent/AU2022311958A1/en active Pending
- 2022-07-14 EP EP22843058.3A patent/EP4370496A4/en active Pending
- 2022-07-14 JP JP2024501929A patent/JP2024525766A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240325319A1 (en) | 2024-10-03 |
| EP4370496A1 (en) | 2024-05-22 |
| WO2023288284A1 (en) | 2023-01-19 |
| JP2024525766A (ja) | 2024-07-12 |
| EP4370496A4 (en) | 2025-07-02 |
| CN117881650A (zh) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012290116B2 (en) | Tropinol esters and related compounds to promote normal processing of APP | |
| US9522124B2 (en) | Methods for treating Alzheimer's disease | |
| KR102472011B1 (ko) | App 의 정상 가공을 촉진하는 화합물 | |
| US20240325319A1 (en) | Inhibitors of amyloid beta oligomerization and therapeutic uses thereof | |
| JP2009521470A (ja) | シヌクレイン障害の治療 | |
| JP2017119722A (ja) | タウ凝集阻害剤 | |
| EP2412705B1 (en) | Novel therapeutic agent for cognitive impairment | |
| EP3641763A2 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| EP4252750A1 (en) | Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease | |
| JP2017214302A (ja) | オートファジー誘導剤 | |
| JP2001255318A (ja) | 神経細胞死抑制作用を有する薬剤及びそのスクリーニング方法 | |
| US20200255492A1 (en) | Leptin peptides and their use for treating neurological disorders | |
| WO2025019870A1 (en) | Use of neuronal nitric oxide synthase inhibitors in alzheimer's disease | |
| JP2008530999A (ja) | ミクログリア促進アミロイド形成のアッセイ | |
| JP2018140958A (ja) | ペリサイトの変成を抑制する剤 | |
| WO2007013147A1 (ja) | 血管新生阻害剤及び血管退縮剤 |